Summit updates survival data for Akeso-partnered lung cancer drug
Seeking Alpha ·
Summit Therapeutics ( SMMT ) lost ~1% in the premarket on Wednesday after the company shared the latest data on overall survival from a late-stage trial for ivonescimab, a lung cancer therapy it is developing with Chinese biotech Akeso ( AKESF ).
AI 시장 분석
Summit Therapeutics released the final overall survival data from the late-stage clinical trial of ivonescimab, a lung cancer treatment being co-developed with Chinese biotech Akeso. Following the news, the stock fell about 1% in the pre-market, showing a somewhat disappointing market reaction. Investors need to closely monitor the specific survival data trends from large-scale clinical results.
하락 영향
- Biotech — The stock fell 1% in the pre-market due to the dissipation of pre-priced expectations and uncertainties following the release of late-stage clinical survival data for ivonescimab.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
469 participants
Related News
- There are opportunities in high-quality growth stocks without paying the price – DCLA’s Sarat Sethi
- U.S. high-yield credit spreads tend to widen into Q4, Topdown Charts says
- Cal-Maine's profit cracks as egg oversupply crushes prices
- Enagás, S.A. reports 1H results
- AT&T beats on profit and subscribers as fiber, wireless momentum accelerates
- Alphabet earnings offer a moment of truth in this tech stock battle
